// App-Quantinova.ai

5047 : Tolerability of [177Lu]Lu-PSMA-617 by treatment exposure in patients with metastatic castration-resistant prostate cancer (mCRPC) A VISION study subgroup analysis.

Researchers

Presenter

  • Scott T. Tagawa

Principal Investigators

  • Andrew J. Armstrong

  • Bernd J. Krause

  • Ken Herrmann

  • Kambiz Rahbar

  • Johann S. De Bono

  • Nabil Adra

  • Michelle Desilvio

  • Richard Messmann

  • Geoffrey Holder

  • Kim N. Chi

Medical Centers

  • Weill Cornell Medicine, New York, NY

  • Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC

  • Department of Ophthalmology, Rostock University Medical Center, Rostock, Germany

  • University Hospital of Essen, Essen, Germany

  • University Hospital of Muenster, Muenster, Germany

  • The Institute of Cancer Research & The Royal Marsden, London, Spain

  • Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Novartis Pharmaceuticals AG, Basel, Switzerland

  • Advanced Accelerator Applications, a Novartis Company, Geneva, Switzerland

  • British Columbia Cancer Agency, Vancouver, BC, Canada

Locations

  • United States

  • Germany

  • United Kingdom

  • Switzerland

  • Canada

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Urology

  • Oncology (ONC)

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Androgen Tear

  • taxane

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multinational

Phase

  • III

Study Id's

  • NCT03511664

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved